Site-specific delivery of inhalable antiangiogenic liposomal dry powder inhaler technology ameliorates experimental pulmonary hypertension
Authors:
- Sagar DhobleSDSagar Dhoble
- Vinod GhodakeVGVinod Ghodake
- Vaibhavi PeshattiwarVPVaibhavi Peshattiwar
- Vandana PatravaleVPVandana Patravale
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 62
Abstract
No abstract availableKeywords
Funding Information
- Instituto de Tecnología Química
This publication has 35 references indexed in Scilit:
- The Pharmacological Treatment of Pulmonary Arterial HypertensionPharmacological Reviews, 2012
- Effect of Sampling Volume on Dry Powder Inhaler (DPI)-Emitted Aerosol Aerodynamic Particle Size Distributions (APSDs) Measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen Eight-Stage Cascade Impactor (ACI)AAPS PharmSciTech, 2012
- Reversible or Irreversible Remodeling in Pulmonary Arterial HypertensionAmerican Journal of Respiratory Cell and Molecular Biology, 2010
- Particle engineering using sonocrystallization: Salbutamol sulphate for pulmonary deliveryInternational Journal of Pharmaceutics, 2009
- Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to MiceAntimicrobial Agents and Chemotherapy, 2008
- Development of Spray Dried Liposomal Dry Powder Inhaler of DapsoneAAPS PharmSciTech, 2008
- In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A reviewAAPS PharmSciTech, 2007
- Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertensionProgress in Cardiovascular Diseases, 2002
- Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3.Journal of Clinical Investigation, 1998
- In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devicesInternational Journal of Pharmaceutics, 1997